Original reporting and analysis on the stories shaping biotech.
The FDA just contacted over 2,200 companies about 3,000 unreported clinical trials, and this time it's not just a friendly reminder. Nearly a third of trials that should have results on ClinicalTrials.gov are completely missing, and the agency's patience is running out.
Former Senator Ben Sasse enrolled in a Revolution Medicines trial for a drug that scientists said couldn't exist, targeting the "undruggable" protein behind 90% of pancreatic cancers. The Phase 3 data that just dropped shows patients living nearly twice as long as those on chemo.
Neomorph just raised $100M to advance a drug that works nothing like traditional medicine: instead of blocking cancer proteins, it glues them to the cell's trash compactor. With Deerfield, Regeneron Ventures, and three Big Pharma partnerships already in hand, the real test starts now.
A company that didn't exist two years ago wants to raise $528.5 million in one of the biggest biotech IPOs of 2026. Kailera Therapeutics is betting the obesity drug market is big enough for one more GLP-1 player, and Bain Capital is putting $225 million where its mouth is.
Amgen and Boehringer Ingelheim both killed immunology programs on the same day, citing slim odds of success. The terminations were tiny, but the signal they send about pharma's tightening standards is anything but.
A protein detection company you've probably never heard of just tripled its revenue and is asking Wall Street for a billion-dollar valuation. Alamar Biosciences is betting that proteins, not just DNA, hold the key to finding diseases early.
AbbVie just licensed two early-stage, non-opioid pain drugs from a Chinese pharma company most people have never heard of, in a deal worth up to $745 million. It's a small upfront bet with massive implications for AbbVie's post-Humira future and the booming China-to-West licensing pipeline.
Eli Lilly just dropped up to $300 million on a two-year-old company with zero drugs in human testing. CrossBridge Bio's dual-payload ADC technology has Big Pharma salivating, and this deal says a lot about where the antibody-drug conjugate arms race is headed.
GSK is launching five Phase 3 trials simultaneously for a gynecologic cancer ADC that posted a 62% response rate in heavily pretreated ovarian cancer patients. It's the company's boldest oncology bet in years, and it's targeting a space the biggest ADC players have mostly ignored.
Boehringer Ingelheim and Amgen both axed immunology programs within weeks of each other, one for futility and one for safety. They're not retreating from the space; they're raising the bar for what deserves to survive.
Regeneron, the antibody powerhouse, just made a surprise $2.1 billion bet on radioactive cancer drugs through a deal with Telix Pharmaceuticals. It's the latest sign that radiopharmaceuticals have gone from niche curiosity to the hottest arms race in oncology.
The FDA just fast-tracked a new guided-missile cancer drug for small cell lung cancer, one of oncology's most brutal diseases. With a 48% response rate where standard options barely move the needle, Daiichi Sankyo and Merck's $4 billion bet might be about to pay off.
Allogene's off-the-shelf CAR-T therapy cleared residual lymphoma cells at 3.5 times the rate of observation alone, with zero serious side effects. If durability data holds, the $10K-per-dose treatment could upend the $400K autologous CAR-T model entirely.
IDEAYA Biosciences just dropped uveal melanoma trial data that more than doubled progression-free survival in patients who had almost no treatment options. Wall Street loved it, an FDA filing is coming, and a half-billion-dollar partnership is fueling what comes next.
Seaport Therapeutics and Hemab Therapeutics both filed $100 million IPOs on the exact same day, targeting depression and rare bleeding disorders respectively. Their simultaneous filings say a lot about where the biotech IPO market stands in Q2 2026.
For 40 years, the RAS protein was cancer research's most infamous failure: too smooth, too stubborn, too "undruggable." Revolution Medicines just posted Phase 3 results that nearly doubled survival in pancreatic cancer patients, and the implications go far beyond one drug.
Gilead Sciences just closed its third acquisition in six weeks, bringing its recent M&A tab to nearly $13 billion. The latest buy: a German ADC biotech that could reshape how cancer drugs find their targets.
Western pharma companies poured $52 billion into Chinese biotech licensing deals in just the first two months of 2026, nearly matching all of 2024 in eight weeks. The shopping spree signals something bigger than bargain hunting: a fundamental power shift in where the world's best drugs are being invented.
Avalyn Pharma wants to take two blockbuster lung disease drugs and reinvent how patients receive them. The company just filed for a $100 million IPO, betting that inhaling these medications beats swallowing them.
A Shanghai biotech just raised $110 million to chase something nobody has achieved: the first CAR-T cell therapy approved for solid tumors. Oricell's early liver cancer data is turning heads, and the IPO clock is ticking.
The FDA rejected Replimune's melanoma gene therapy RP1 for the second time, citing the same trial design flaws it flagged five years ago. The decision sends a chilling message to every company betting on oncolytic virus therapies with single-arm studies.
The FDA just approved Eli Lilly's Foundayo, an oral GLP-1 pill for obesity that you can pop any time of day without fasting or needles. With two-thirds of injectable patients quitting within a year, this little tablet could blow the market wide open.
Join thousands of biotech professionals who start their day with our free, daily briefing.